Filtros de búsqueda

Lista de obras de

2020 Innovation Based Optimism for Lung Cancer Outcomes

artículo científico publicado en 2020

A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer

artículo científico publicado en 2011

Characteristics of lung cancers harboring NRAS mutations

artículo científico publicado en 2013

Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium

artículo científico publicado en 2014

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

artículo científico publicado en 2005

Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

artículo científico publicado en 2003

Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer

artículo científico publicado en 2006

FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies.

artículo científico publicado en 2014

In Reply

Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy

artículo científico publicado en 2008

Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression

artículo científico publicado en 2010

Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer

artículo científico publicado el 1 de diciembre de 2012

Malignant pleural disease is highly associated with subsequent peritoneal metastasis in patients with stage IV non-small cell lung cancer independent of oncogene status

artículo científico publicado en 2016

Molecularly targeted therapies in non-small-cell lung cancer annual update 2014

artículo científico publicado en 2015

Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience

artículo científico publicado en 2015

New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer

scientific article published on 25 January 2010

Oncogene status predicts patterns of metastatic spread in treatment‐naive nonsmall cell lung cancer

artículo científico publicado el 26 de enero de 2012

Preclinical studies of gemcitabine and trastuzumab in breast and lung cancer cell lines.

artículo científico publicado en 2002

Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer

artículo científico publicado en 2013

Scientific Advances in Lung Cancer 2015.

artículo científico publicado en 2016

Summary report 7th Annual Targeted Therapies of the Treatment of Lung Cancer

artículo científico publicado en 2008

The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016.

artículo científico publicado en 2016

The evolution of tumor classification: a role for genomics?

artículo científico publicado en 2013

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs

artículo científico publicado en 2014